By Nicholas Hatcher
Amgen Inc. (AMGN) said its Phase 3 trial studying its Evolocumab
cholesterol drug met its primary endpoint of the reduction in
LDL-C, or "bad" cholesterol.
The Thousand Oaks, Calif., pharmaceutical company said its TESLA
trial of Evolocumab "in patients with homozygous familial
hypercholesterolemia, a rare and serious disease" demonstrated
positive top-line results.
Safety was generally balanced across treatment groups, the
company said, and the most common adverse events were upper
respiratory tract infection, influenza, gastroenteritis and
nasopharyngitis.
Evolocumab is an investigational fully human monoclonal antibody
that inhibits a protein that reduces the liver's ability to remove
bad cholesterol from the blood.
Write to Nicholas Hatcher at nicholas.hatcher@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires